1-3 of 3
Erik van Beers, PhD
Close
Sort by
Journal Articles

Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

Erik van Beers, PhD, Martin van Vliet, PhD, Leonie de Best, MSc, Kenneth C. Anderson, MD, Ajai Chari, MD, Sundar Jagganath, MD, Andrzej Jakubowiak, MD PhD, Shaji K. Kumar, MD, Daniel Lebovic, MD, Joan Levy, PhD, Daniel Auclair, PhD, Sagar Lonial, MD, Donna Reece, MD, Paul G. Richardson, MD, David Siegel, MD PhD, A. Keith Stewart, MBA, MB, CHB, Suzanne Trudel, MD, Ravi Vij, MD, Todd Zimmerman, MD, Rafael Fonseca, MD
Journal: Blood
Blood (2015) 126 (23): 5322.
https://doi.org/10.1182/blood.V126.23.5322.5322
Published: 2015
Journal Articles

Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma

Mark van Duin, PhD, Rowan Kuiper, BSc, Martin van Vliet, PhD, Annemiek Broijl, MD PhD, Leonie de Best, MSc, Erik van Beers, PhD, Bronno Van Der Holt, PhD, Heleen Visser-Wisselaar, PhD, Lizanne Bosman, BSc, Belinda Dumee, BSc, Fanni van den Bosch, BSc, Michael Vermeulen, BSc, Jasper Koenders, BSc, Marian Stevens-Kroef, PhD, Anders Waage, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2967.
https://doi.org/10.1182/blood.V126.23.2967.2967
Published: 2015
Journal Articles

The Combination of SKY92 and ISS Provides a Powerful Tool to Identify Both High Risk and Low Risk Multiple Myeloma Cases, Validation in Two Independent Cohorts

Martin van Vliet, PhD, Joske Ubels, MSc, Leonie de Best, MSc, Erik van Beers, PhD, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2970.
https://doi.org/10.1182/blood.V126.23.2970.2970
Published: 2015